Prot #VX14-661-108: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous f

Project: Research project

StatusFinished
Effective start/end date12/4/1512/4/18

Funding

  • Quintiles, Inc. (Prot #VX14-661-108)
  • Vertex Pharmaceuticals Incorporated (Prot #VX14-661-108)